Collegium Pharmaceutical, Inc.COLLNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +21.51% | +22.66% | +29.41% | +31.42% | +12.92% |
| Gross Profit Growth | +3.87% | +6.42% | +19.36% | +33.45% | +30.61% |
| EBITDA Growth | -4.95% | -9.98% | +17.40% | +60.73% | +214.79% |
| Operating Income Growth | -38.22% | -56.16% | -26.05% | +82.61% | +55.40% |
| Net Income Growth | -60.75% | -91.28% | -38.88% | +237.51% | +35.31% |
| EPS Growth | -60.61% | -91.16% | -36.67% | +203.03% | +38.46% |
| EPS Diluted Growth | -57.32% | -89.63% | -34.62% | +211.11% | +31.43% |
| Weighted Average Shares Growth | -0.69% | -1.65% | -1.92% | -2.13% | -1.16% |
| Weighted Average Shares Diluted Growth | -2.84% | -20.75% | -3.24% | -1.80% | -1.02% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +15.42% | -10.56% | +7.48% | +0.00% | +45.37% |
| Free Cash Flow Growth | +14.90% | -11.03% | +7.81% | +0.00% | +45.54% |
| Receivables Growth | +27.30% | +30.92% | +15.86% | +2.40% | -7.53% |
| Inventory Growth | +9.98% | +19.00% | +36.92% | +0.05% | +15.05% |
| Asset Growth | +45.51% | +46.41% | +51.19% | -1.70% | -0.41% |
| Book Value per Share Growth | +17.91% | +7.29% | +9.31% | +19.86% | +33.37% |
| Debt Growth | +27.44% | +34.00% | +48.20% | +7.08% | +9.46% |
| R&D Expense Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| SG&A Expenses Growth | +91.52% | +82.04% | +69.93% | +5.80% | +7.21% |